Biosimilar showdown: new drug tested against opdivo in melanoma
NCT ID NCT06587451
First seen Mar 09, 2026 · Last updated Apr 24, 2026 · Updated 3 times
Summary
This study tested a new biosimilar drug (JPB898) against the approved immunotherapy Opdivo, both given with Yervoy, in people with advanced melanoma that cannot be removed by surgery. The goal was to see if the biosimilar works as well and is as safe as the original. The trial was terminated early, and only 52 people took part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sandoz Investigational Site
Santiago, Chile
-
Sandoz Investigational Site
Athens, Greece
-
Sandoz Investigational Site
Thessaloniki, Greece
-
Sandoz Investigational Site
Pisa, Italy
-
Sandoz Investigational Site
Vilnius, Lithuania
-
Sandoz Investigational Site
Kuala Lumpur, Malaysia
-
Sandoz Investigational Site
Pulau Pinang, Malaysia
-
Sandoz Investigational Site
Putrajaya, Malaysia
-
Sandoz Investigational Site
Bacolod, Philippines
-
Sandoz Investigational Site
Warsaw, Poland
-
Sandoz Investigational Site
Lisbon, Portugal
-
Sandoz Investigational Site
Daejeon, South Korea
-
Sandoz Investigational Site
Málaga, Spain
-
Sandoz Investigational Site
Oviedo, Spain
-
Sandoz Investigational Site
Santander, Spain
-
Sandoz Investigational Site
Santiago de Compostela, Spain
-
Sandoz Investigational Site 1
Santiago, Chile
-
Sandoz Investigational Site 1
Busan, South Korea
-
Sandoz Investigational Site 2
Tbilisi, Georgia
-
Sandoz Investigational Site 2
Seoul, South Korea
-
Sandoz Investigational Site 2
Madrid, Spain
-
Sandoz Investigational Site 2
Valencia, Spain
Conditions
Explore the condition pages connected to this study.